Infant respiratory distress syndrome (IRDS) is an acute respiratory illness that affects newborns, especially premature infants. The condition results from a deficiency of surfactant, a substance produced by the alveolar cells of the lungs that helps prevent the alveoli from collapsing. Symptoms include difficulty breathing, cyanosis, tachypnea, and use of accessory muscles of respiration. IRD can cause significant complications and is a medical emergency because the condition can rapidly worsen, leading to the need for oxygen therapy or mechanical ventilation.
History of the disease and interesting historical facts
The history of IRS dates back to the mid-20th century, when clinical features of the condition were first described in the 1960s. One of the first to draw attention to the problem was J.C. Levine, who in 1965 published an article about the syndrome observed in premature infants. Over the next decades, numerous studies were conducted, which led to the identification of the causes of the disease, including surfactant deficiency. In the 1980s, the development of exogenous surfactant significantly improved the treatment outcomes for infants with IRS, saving many lives. Thanks to modern medical monitoring and treatment technologies, infant mortality from IRS has decreased by 50% or more over the past 30 years.
Epidemiology
Infant respiratory distress syndrome is statistically most common in premature infants. According to recent studies, the diagnosis is made in approximately 25-30% of all low birth weight newborns, and in children weighing less than 1500 g, SRDS develops in 50-70% cases. With age, the risk of the disease increases: premature infants from the 28th week of pregnancy have the greatest predisposition. It is important to note that the disease can also develop among full-term infants, although this is relatively rare - less than 5% cases.
Genetic predisposition to this disease
Genetic factors play a role in the predisposition to respiratory distress syndrome in infants. In particular, mutations in genes associated with surfactant production, such as SFTPB, SFTPC, and ABCA3, may increase the risk of developing SRDS. Familial cases of the disease indicate a hereditary predisposition. Research shows that some gene variations may affect the level of surfactant expression, which in turn affects the lung health of newborns. However, in addition to genetic factors, non-genetic factors such as premature birth and Geburt's asphyxia also influence the development of SRDS.
Risk factors for the development of this disease
The risk of developing respiratory distress syndrome in infants is determined by both physical and chemical factors. The most important risk factors include:
- Prematurity: the most significant predictor increasing the likelihood of SRDM.
- Birth weight: Low birth weight is associated with a high predisposition.
- Multiple pregnancy: Having twins or triplets increases the risk of prematurity and, consequently, SIDS.
- Obstetric factors: infection, advanced pregnancy problems, preeclampsia.
- Environmental conditions: exposure to toxic substances or pollutants during pregnancy.
These factors may further aggravate the condition of newborns, predisposing them to the development of SRD, which requires careful monitoring and preventive measures.
Diagnosis of this disease
Diagnosis of respiratory distress syndrome in infants involves a comprehensive and multi-step approach. The main symptoms that doctors pay attention to include:
- Difficulty breathing (tachypnea).
- Cyanosis or bluish discoloration of the skin, especially around the lips and extremities.
- Use of accessory respiratory muscles, which is clearly visible by the retraction of the intercostal spaces and jugular fossa.
Laboratory tests may include blood gas analysis to assess oxygen and carbon dioxide levels. Radiological tests usually include a chest X-ray, which may show characteristic changes such as bright spots (interstitial edema) and slow glass signs, indicating fluid in the lungs. Other tests may include ultrasound to assess lung structure.
Differential diagnosis is important to exclude other diseases with a similar clinical picture, such as pneumonia, herpes infection and aspiration pneumonia.
Treatment
Treatment of respiratory distress syndrome in infants requires a multidisciplinary approach. General first aid measures include ensuring normal oxygenation and maintaining the infant's body temperature. Pharmacological treatment usually includes:
- Exogenous surfactant administered intratracheally, which significantly improves pulmonary function.
- Oxygen therapy to maintain oxygen levels.
- Systemic steroids to reduce inflammation and pulmonary edema.
In some cases, ventilation may be performed using noninvasive mechanical ventilation techniques or intubation. Surgical treatment is not usually used, but in rare cases, intervention may be required to address other causes of respiratory distress.
Other treatments may include chest massage or physical therapy, which helps improve drainage of lung fluid and respiratory health.
List of medications used to treat this disease
Medications used to treat infant respiratory distress syndrome include:
- Exogenous surfactants (for example, berechent or sinokot).
- Glucocorticoids (eg, dexamethasone).
- Oxygen gas mixtures to support oxygenation.
These medications are the main tools in the fight against the syndrome and help reduce the risk of serious complications inherent in this condition.
Disease monitoring
Once treatment for infant respiratory distress syndrome has begun, ongoing monitoring is required. Monitoring steps include:
- Regular blood gas measurements to monitor oxygen and carbon dioxide levels.
- Monitoring the dynamics of pulmonary function through chest radiography.
- Assessment of clinical parameters such as respiratory rate, heart rate and general condition.
The prognosis depends on the severity of the condition, the time of initiation of treatment, and the overall clinical background. Possible complications include bronchopulmonary dysplasia, infections, and chronic lung disease.
Age-related features of the disease
Respiratory distress syndrome is most often seen in premature infants, but it can occur in full-term infants. In newborns, the disease is often severe with obvious symptoms, while in older children the symptoms may be milder. The risk of complications is increased in premature infants due to structural immaturity of the lungs and lack of surfactant. As the lung tissue grows and develops, most infants recover completely, but in some cases the syndrome can cause chronic lung problems.
Questions and Answers
- What are the main symptoms of SRDM in infants? The main symptoms include difficulty breathing, cyanosis, and use of accessory muscles of respiration.
- What is the risk of developing preterm infant syndrome? The risk is very high and can reach 50-70% in children with a birth weight of less than 1500 g.
- What is the role of exogenous surfactant in treatment? Exogenous surfactant significantly improves pulmonary function, which is critical for successful treatment of SRDM.
- What are the possible complications of SRDM? Possible complications include bronchopulmonary dysplasia, infections, and chronic lung disease.
- What are the preventive measures to prevent SRDM? Prevention includes optimisation of pregnancy, monitoring of birth conditions and early intensive care for preterm infants.
Dr. Oleg Korzhikov, a pediatrician with extensive experience, recommends not ignoring the symptoms of respiratory distress syndrome and seeking medical help immediately if alarming signs occur. "Timely diagnosis and treatment of RDS significantly increase the chances of a successful outcome," he says. Also, if there are predispositions, it is important to carefully monitor babies in maternity hospitals to prevent the development of severe complications.
